↓ Skip to main content

Future options of anti‐angiogenic cancer therapy

Overview of attention for article published in Cancer Communications, February 2016
Altmetric Badge

Mentioned by

twitter
6 X users

Citations

dimensions_citation
40 Dimensions

Readers on

mendeley
62 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Future options of anti‐angiogenic cancer therapy
Published in
Cancer Communications, February 2016
DOI 10.1186/s40880-016-0084-4
Pubmed ID
Authors

Yihai Cao

Abstract

In human patients, drugs that block tumor vessel growth are widely used to treat a variety of cancer types. Many rigorous phase 3 clinical trials have demonstrated significant survival benefits; however, the addition of an anti-angiogenic component to conventional therapeutic modalities has generally produced modest survival benefits for cancer patients. Currently, it is unclear why these clinically available drugs targeting the same angiogenic pathways produce dissimilar effects in preclinical models and human patients. In this article, we discuss possible mechanisms of various anti-angiogenic drugs and the future development of optimized treatment regimens.

X Demographics

X Demographics

The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 62 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 62 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 15 24%
Student > Master 10 16%
Student > Bachelor 8 13%
Student > Doctoral Student 6 10%
Researcher 4 6%
Other 8 13%
Unknown 11 18%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 14 23%
Agricultural and Biological Sciences 9 15%
Pharmacology, Toxicology and Pharmaceutical Science 8 13%
Medicine and Dentistry 8 13%
Engineering 6 10%
Other 6 10%
Unknown 11 18%